ACP 204
Alternative Names: ACP-204Latest Information Update: 01 Jul 2025
At a glance
- Originator ACADIA Pharmaceuticals
- Class Antidementias; Antipsychotics; Behavioural disorder therapies
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Psychotic disorders
- Preclinical Lewy body disease
Most Recent Events
- 30 Jun 2025 ACADIA Pharmaceuticals plans a phase II trial for Lewy body disease, in June 2025 (PO, Capsule) (NCT07029581; EUCT2025-521710-25-00)
- 26 Jun 2025 Preclinical trials in Lewy body disease in USA (unspecified route)
- 23 Apr 2024 Phase-III clinical trials in Psychotic disorders in USA (PO, Capsule) (NCT06194799)